Show simple item record

AuthorMoustafa, Diala Alhaj
AuthorImran, Zainab
AuthorIsmail, Roua
AuthorRayan, Menatallah
AuthorGadeau, Alain Pierre
AuthorEldassouki, Hussein
AuthorAbdulrahman, Nabeel
AuthorMraiche, Fatima
Available date2023-03-27T10:19:21Z
Publication Date2022-03-01
Publication NameMolecular Biology Reports
Identifierhttp://dx.doi.org/10.1007/s11033-022-07183-w
CitationMoustafa, D.A., Imran, Z., Ismail, R. et al. Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study. Mol Biol Rep 49, 2321–2324 (2022). https://doi.org/10.1007/s11033-022-07183-w
ISSN03014851
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85124154184&origin=inward
URIhttp://hdl.handle.net/10576/41352
AbstractNumerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.
SponsorThis project was supported by Qatar University Student Grant No: QUST-2-CPH-2020-16. “The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.”
Languageen
PublisherSpringer
SubjectACE-2
COVID-19
Dapagliflozin
DARE-19
Renin angiotensin aldosterone system
SGLT-2
TitleEvaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study
TypeArticle Review
Pagination2321-2324
Issue Number3
Volume Number49
ESSN1573-4978
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record